These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 8136894

  • 1. Growth hormone secretion in Alzheimer's disease: studies with growth hormone-releasing hormone alone and combined with pyridostigmine or arginine.
    Ghigo E, Nicolosi M, Arvat E, Marcone A, Danelon F, Mucci M, Franceschi M, Smirne S, Camanni F.
    Dementia; 1993; 4(6):315-20. PubMed ID: 8136894
    [Abstract] [Full Text] [Related]

  • 2. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging.
    Ghigo E, Goffi S, Arvat E, Nicolosi M, Procopio M, Bellone J, Imperiale E, Mazza E, Baracchi G, Camanni F.
    Acta Endocrinol (Copenh); 1990 Aug; 123(2):169-73. PubMed ID: 2220258
    [Abstract] [Full Text] [Related]

  • 3. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E.
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [Abstract] [Full Text] [Related]

  • 4. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E, Di Vito L, Ramunni J, Gianotti L, Giordano R, Deghenghi R, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [Abstract] [Full Text] [Related]

  • 5. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [Abstract] [Full Text] [Related]

  • 6. Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa.
    Ghigo E, Arvat E, Gianotti L, Nicolosi M, Valetto MR, Avagnina S, Bellitti D, Rolla M, Müller EE, Camanni F.
    Biol Psychiatry; 1994 Nov 15; 36(10):689-95. PubMed ID: 7880938
    [Abstract] [Full Text] [Related]

  • 7. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
    Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E, Ghigo MC, Camanni F.
    J Clin Endocrinol Metab; 1990 Dec 15; 71(6):1481-5. PubMed ID: 2229304
    [Abstract] [Full Text] [Related]

  • 8. A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging.
    Ghigo E, Goffi S, Arvat E, Imperiale E, Boffano GM, Valetto MR, Mazza E, Santi I, Magliona A, Boghen MF.
    J Endocrinol Invest; 1992 Oct 15; 15(9):665-70. PubMed ID: 1479149
    [Abstract] [Full Text] [Related]

  • 9. Effect of 15-day treatment with growth-hormone-releasing hormone alone or combined with different doses of arginine on the reduced somatotrope responsiveness to the neurohormone in normal aging.
    Ghigo E, Ceda GP, Valcavi R, Goffi S, Zini M, Mucci M, Valenti G, Muller EE, Camanni F.
    Eur J Endocrinol; 1995 Jan 15; 132(1):32-6. PubMed ID: 7850007
    [Abstract] [Full Text] [Related]

  • 10. Arginine potentiates the GHRH- but not the pyridostigmine-induced GH secretion in normal short children. Further evidence for a somatostatin suppressing effect of arginine.
    Ghigo E, Bellone J, Mazza E, Imperiale E, Procopio M, Valente F, Lala R, De Sanctis C, Camanni F.
    Clin Endocrinol (Oxf); 1990 Jun 15; 32(6):763-7. PubMed ID: 1974484
    [Abstract] [Full Text] [Related]

  • 11. The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome.
    Arvat E, Gianotti L, Ragusa L, Valetto MR, Cappa M, Aimaretti G, Ramunni J, Grottoli S, Camanni F, Ghigo E.
    Dementia; 1996 Jun 15; 7(5):288-92. PubMed ID: 8872421
    [Abstract] [Full Text] [Related]

  • 12. The role of cholinergic tone in modulating the growth hormone response to growth hormone-releasing hormone in normal man.
    Giustina A, Bossoni S, Bodini C, Doga M, Girelli A, Buffoli MG, Schettino M, Wehrenberg WB.
    Metabolism; 1991 May 15; 40(5):519-23. PubMed ID: 2023538
    [Abstract] [Full Text] [Related]

  • 13. Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of corticotropin-releasing hormone on the growth hormone-releasing hormone-induced growth hormone secretion.
    Corsello SM, Tofani A, Della Casa S, Sciuto R, Rota CA, Colasanti S, Bini A, Barini A, Barbarino A.
    Acta Endocrinol (Copenh); 1992 Feb 15; 126(2):113-6. PubMed ID: 1543015
    [Abstract] [Full Text] [Related]

  • 14. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L, Marziani E, Manzoni P, Arvat E, Valetto MR, Gianotti L, Ghigo E, Chiumello G.
    Dement Geriatr Cogn Disord; 1998 Feb 15; 9(2):78-81. PubMed ID: 9524798
    [Abstract] [Full Text] [Related]

  • 15. Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine.
    Procopio M, Maccario M, Grottoli S, Oleandri SE, Boffano GM, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1995 Dec 15; 43(6):665-9. PubMed ID: 8736266
    [Abstract] [Full Text] [Related]

  • 16. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
    Cordido F, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1990 May 15; 70(5):1361-70. PubMed ID: 2159483
    [Abstract] [Full Text] [Related]

  • 17. Effect of cholinergic tone on growth hormone-releasing hormone-induced secretion of growth hormone in normal aging.
    Giusti M, Marini G, Sessarego P, Peluffo F, Valenti S, Caratti C, Giordano G.
    Aging (Milano); 1992 Sep 15; 4(3):231-7. PubMed ID: 1420407
    [Abstract] [Full Text] [Related]

  • 18. GH secretion in Prader-Labhard-Willi syndrome: somatotrope responsiveness to GHRH is enhanced by arginine but not by pyridostigmine.
    Beccaria L, Bosio L, Sanzari A, Aimaretti G, Ghigo E, Chiumello G.
    J Pediatr Endocrinol Metab; 1996 Sep 15; 9(6):577-83. PubMed ID: 9004172
    [Abstract] [Full Text] [Related]

  • 19. Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women.
    Arvat E, Cappa M, Casanueva FF, Dieguez C, Ghigo E, Nicolosi M, Valcavi R, Zini M.
    J Clin Endocrinol Metab; 1993 Feb 15; 76(2):374-7. PubMed ID: 8432781
    [Abstract] [Full Text] [Related]

  • 20. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1989 Feb 15; 68(2):290-3. PubMed ID: 2493023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.